AstraZeneca (AZN) Given a GBX 4,550 Price Target at UBS Group

UBS Group set a GBX 4,550 ($61.70) price objective on AstraZeneca (LON:AZN) in a report published on Monday, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Citigroup set a GBX 6,000 ($81.37) price target on AstraZeneca and gave the stock a buy rating in a research report on Wednesday, September 13th. Berenberg Bank restated a buy rating and set a GBX 5,500 ($74.59) price target on shares of AstraZeneca in a research report on Monday, September 11th. Deutsche Bank increased their price target on AstraZeneca from GBX 5,300 ($71.87) to GBX 5,600 ($75.94) and gave the stock a buy rating in a research report on Monday, September 11th. Liberum Capital restated a buy rating and set a GBX 4,800 ($65.09) price target on shares of AstraZeneca in a research report on Monday, September 11th. Finally, Societe Generale restated a buy rating on shares of AstraZeneca in a research report on Monday, September 11th. Four research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of Hold and an average target price of GBX 5,200.82 ($70.53).

Shares of AstraZeneca (AZN) opened at GBX 5,136 ($69.65) on Monday. The company has a market capitalization of $65,180.00 and a P/E ratio of 2,481.16. AstraZeneca has a 12-month low of GBX 4,136.50 ($56.10) and a 12-month high of GBX 5,520 ($74.86).

COPYRIGHT VIOLATION WARNING: “AstraZeneca (AZN) Given a GBX 4,550 Price Target at UBS Group” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.themarketsdaily.com/2018/01/11/astrazeneca-azn-given-a-gbx-4550-price-target-at-ubs-group.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply